Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTrellus Health. Regulatory News (TRLS)

Share Price Information for Trellus Health. (TRLS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.25
Bid: 2.00
Ask: 2.50
Change: 0.35 (18.42%)
Spread: 0.50 (25.00%)
Open: 1.90
High: 2.25
Low: 1.90
Prev. Close: 1.90
TRLS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

16 Apr 2024 17:02

RNS Number : 8598K
Trellus Health PLC
16 April 2024
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BNNFM402

Issuer Name

TRELLUS HEALTH PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Harwood Capital LLP

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

Name

City of registered office

Country of registered office

Harwood Capital Management (Gibraltar) Limited

Gibraltar

Gibraltar

Harwood Capital LLP

London

United Kingdom

4. Details of the shareholder

Name

City of registered office

Country of registered office

North Atlantic Smaller Companies Investment Trust Plc

London

United Kingdom

Oryx International Growth Fund Limited

Guernsey

Guernsey

Harwood Capital LLP

London

United Kingdom

5. Date on which the threshold was crossed or reached

12 04 2024

6. Date on which Issuer notified

16 04 24

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

10.760800

0.000000

10.760800

17,379,667

Position of previous notification (if applicable)

12.680300

0.000000

12.680300

20479667

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BNNFM402

12,000,000

7.430000

GB00BNNFM402

2,050,000

 

1.269300

 

GB00BNNFM402

 

3,329,667

 

 

2.061600

 

Sub Total 8.A

17,379,667

10.760800 %

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Christopher Harwood Bernard Mills

Harwood Capital LLP

10.760800

 

10.760800%

 

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

16/04/24

13. Place Of Completion

London Stock Exchange

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLEAKLKFEELEFA
12
Date   Source Headline
23rd Apr 20247:00 amRNSPreliminary Results
17th Apr 20244:16 pmRNSHolding(s) in Company
16th Apr 20245:02 pmRNSHolding(s) in Company
16th Apr 20247:00 amRNSNotice of Results
2nd Apr 20244:36 pmRNSHolding(s) in Company
5th Mar 20247:00 amRNSGrant of Share Options
28th Feb 202412:00 pmRNSDirectorate Change
28th Feb 20247:00 amRNSAgreement with US Health Plan
28th Sep 20237:00 amRNSHalf-year Report
14th Sep 20237:00 amRNSNotice of Results
12th Sep 20237:00 amRNSAppointment of Chief Financial Officer
22nd Jun 20231:37 pmRNSResult of AGM
13th Jun 20237:00 amRNSRelated Party Transactions
26th May 20237:00 amRNSPosting of Annual Report and Notice of AGM
23rd May 20237:00 amRNSFinal Results
28th Apr 20237:00 amRNSNotice of Results
6th Mar 20237:00 amRNSTrading Update
17th Feb 20237:00 amRNSLaunch of D2C IBS Offering
13th Feb 20237:00 amRNSNew York Medicaid Health Plan Agreement
6th Feb 20237:01 amRNSDirectorate Change
20th Dec 20227:00 amRNSTrading Update & Related Party Transaction
14th Dec 20225:28 pmRNSHolding(s) in Company
19th Oct 20227:00 amRNSTrellus IBD program launches on GI OnDEMAND
17th Oct 20227:00 amRNSTwo contracts signed with Mount Sinai
5th Oct 20229:06 amRNSSecond Price Monitoring Extn
5th Oct 20229:00 amRNSPrice Monitoring Extension
30th Sep 20224:41 pmRNSSecond Price Monitoring Extn
30th Sep 20224:35 pmRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSHalf-year Report
26th Sep 20227:00 amRNSMarla Dubinsky a recipient of 2022 Sherman Prize
22nd Sep 20227:00 amRNSNotice of Results and Investor Presentation
1st Aug 20227:00 amRNSAppointment of Chief Financial Officer
19th Jul 20227:00 amRNSDirectorate Changes
27th Jun 20222:47 pmRNSResult of AGM and voting results
23rd Jun 20227:00 amRNSDirectorate Change
25th May 202212:00 pmRNSPosting of Annual Report & Accounts
10th May 20227:01 amRNSInvestor Presentation
10th May 20227:00 amRNSFinal Results
7th Apr 20227:00 amRNSNotice of Results
28th Feb 20227:00 amRNSDirect to Consumer market launch in New York
21st Jan 20227:00 amRNSAppointment of Chief Financial Officer
17th Jan 20227:00 amRNSClinical research update on GRITT(tm) methodology
4th Jan 20227:00 amRNSDirectorate Change
20th Dec 20213:44 pmRNSIssue of Equity
14th Dec 20217:00 amRNSTrading update
22nd Sep 20217:00 amRNSHalf-year Report
16th Sep 20217:00 amRNSNew Partnership Agreement & Licensed Clinical Team
9th Sep 20217:00 amRNSNotice of Results
23rd Aug 20217:00 amRNSFirst Demonstration Programme Contract
11th Jun 20214:40 pmRNSSecond Price Monitoring Extn
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.